Latigo Biotherapeutics reports positive mid-stage data for acute-pain drug candidate

Latigo Biotherapeutics announced successful Phase 2 results for its non-opioid pain medication, positioning it as a direct competitor to Vertex Pharmaceuticals' Journavx. The data suggests potential efficacy in acute pain management, though long-term safety and regulatory approval remain uncertain.